CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $4.0B
- Net income
- -$144.3M
- Total assets
- $7.1B
- Market cap
- $8.7B
- Operating margin
- 0.6%
- Net margin
- -3.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.0B
- Operating expenses
- $4.0B
- Operating income
- $25.2M
- Income tax
- $42.7M
- Net income
- -$142.2M
- EPS (basic)
- $-2.91
- EPS (diluted)
- $-2.91
Balance sheet
- Total assets
- $7.1B
- Current assets
- $1.4B
- Total liabilities
- $3.9B
- Current liabilities
- $1.1B
- Shareholders’ equity
- $3.2B
Cash flow
- Operating cash flow
- $737.6M
- Investing cash flow
- -$209.3M
- Financing cash flow
- -$536.7M
- Net cash flow
- $10.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $8.7B
- EPS (diluted)
- $-2.91
- Shares outstanding
- 46.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 23, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $144.3M in FY2025.
- Revenue grew 13% from FY2021 to FY2025.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
Write a review
News about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
News & sentiment via Polygon.io
